Chemistry: molecular biology and microbiology – Enzyme – proenzyme; compositions thereof; process for... – Hydrolase
Patent
1996-03-25
1998-08-25
Robinson, Douglas M.
Chemistry: molecular biology and microbiology
Enzyme , proenzyme; compositions thereof; process for...
Hydrolase
4351723, 4353201, 435325, 536 232, 536 235, C12N 918, C12N 1512, C12N 1552, C12N 1585
Patent
active
057982465
ABSTRACT:
The present invention relates to a heretofore uncharacterized family of cyclic nucleotide phosphodiesterases (CN PCD8) and provides specific polynucleotide and amino acid sequences which encode and identify CN PDE8 family members designated herein as CN PDE8A and CN PDE8B. The present invention also relates to the use of proteins, peptides and organic molecules capable of modulating CN PDE8 activity to inhibit or enhance phosphodiesterase activity associated with disease. The present invention further relates to the use of CN PDE8 and genetically engineered host cells that express CN PDE8 to evaluate and screen for substances and compounds that modulate cyclic nucleotide phosphodiesterase activity. The present invention also provides for cn pde8 antisense molecules. The invention provides genetically engineered expression vectors and host cells for the production of purified CN PDE8 polypeptide. The present invention further provides pharmaceutical compositions and methods of treatment based on the identification of agonist, antagonists and inhibitors of CN PDE8. The invention specifically provides for use of the cn pde8 polynucleotide sequences as a diagnostic composition for the detection of disease.
REFERENCES:
Angel, J.B. et al., "Rolipram, a specific type IV phosphodiestesterase inhibitor, is a potent inhibitor of HIV-1 replication", AIDS (1995) 9:1137-1144.
Bang, Y.J. et al., "Terminal neuroendocrine differentiation of human prostate carcinoma cells in response to increased intracellular cyclic AMP", Proc Natl Acad Sci USA (1994) 91:5330-5334.
Banner, K.H. and Page, C.P., "Immunomodulatory actions of xantines and isoenzyme selective phosphodiesterase inhibitors", Mondaldi Arch Chest Dis (1995) 50:4,286-292.
Banner, K.H. and Page, C.P., "Theophylline and selective phosphodiesterase inhibitors as anti-inflammatory drugs in the treatment of bronchial asthma", Eur Respir J (1995) 8:996-1000.
Beavo, Joseph A., "Cyclic Nucleotide Phosphodiesterases: Functional Implications of Multiple Isoforms", Physiological Reviews (1995) 75:725-747.
Deonarain, M.P. and Epenetos, A.A., "Targeting enzymes for cancer therapy: old enzymes in new roles", (1994) Br J Cancer 70:786-794.
Joulain, C. et al., "Influence of polyunsaturated fatty acids on lipid metabolism in human blood mononuclear cells and early biochemical events associated with lymphocyte activation", J Lipid Mediators Cell Signalling (1995) 11:63-79.
Matousovic, K. et al., "Inhibitors of Cyclic Nucleotide Phosphodiesterase Isozymes Type-III and Type-IV Suppress Mitogenesis of Rat Mesangial Cells", J Clin Invest (1995) 96:401-410.
Sasaki, H. et al., "Suppression of oro-facial movements by rolipram, a cAMP phosphodiesterase inhibitor, in rats chronically treated with haloperidol", European Journal of Pharmacology (1995) 282:71-76.
Sommer, N., "The antidepressant rolipram suppresses cytokine produciton and prevents autoimmune encephalomyelitis", Nature Medicine (1995) 1:244-248.
Thompson, W. J., "Cyclic Nucleotide Phosphodiesterases: Pharmacology, Biochemistry and Function", Pharmac Ther (1991) 51:13-33.
Verghese, M.W. et al., "Regulation of Distinct Cyclic AMP-Specific Phosphodiesterase (Phosphodiesterase Type 4) Isozymes in Human Monocytic Cells", Molecular Pharmacology (195) 47:1164-1171.
Hillier L, et al. "zh47a11.r1 Soares fetal liver spleen 1NFLS S1 Homo sapiens cDNA clone 415196 5" EST Accession No. W91922., Jul. 16, 1996.
Au-Young Janice
Cocks Benjamin Graeme
Coleman Roger
Seilhamer Jeffrey J.
Billings Lucy J.
Incyte Pharmaceuticals Inc.
Nelson Amy J.
Robinson Douglas M.
LandOfFree
Cyclic nucleotide phosphodiesterase does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Cyclic nucleotide phosphodiesterase, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cyclic nucleotide phosphodiesterase will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-35621